BioNTech: We Could Produce New COVID Variant Vaccine In Six Weeks, If Needed
Confident That Existing Vaccine Still Works
The speed of the new messenger RNA platforms could once again come to the rescue, but fortunately the existing vaccines should remain effective against the emerging strain.
You may also be interested in...
US FDA considering approach that is similar to, but more stringent than, influenza strain changes, CBER Director Marks says. Meanwhile, vaccine developers face challenge of when to change antigens to get the best results, NIH’s Graham notes. As FDA and sponsors gain more experience with tweaking the vaccines to account for new coronavirus variants and strains, the process may be expedited further.
The company is developing a vaccine with both adenoviral and mRNA technology that could potentially overcome resistance mutations on the SARS-CoV-2 spike protein.
UK regulator admits evidence sparse on older patients, but believes longer gap between doses can boost efficacy and accelerate numbers of people immunized.